Detalles de la búsqueda
1.
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Cytotherapy
; 24(7): 742-749, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219582
2.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Oncologist
; 23(6): 654-e58, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438092
3.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(4): 375-e30, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28275117
4.
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
Oncologist
; 22(9): 1024-e89, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28592615
5.
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Cancer
; 122(24): 3803-3811, 2016 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27525588
6.
Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Am J Nephrol
; 40(1): 75-83, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25059491
7.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(10): 1281, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29018169
8.
Phase I study of the anti-α5ß1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 82(2): 339-351, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29905898
9.
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
Clin Cancer Res
; 24(10): 2276-2284, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29506988
10.
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
J Immunother Cancer
; 6(1): 61, 2018 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29921320
11.
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
Front Oncol
; 6: 232, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27843803
Resultados
1 -
11
de 11
1
Próxima >
>>